Proenkephalin B (prodynorphin)-derived Opioid Peptides: Evidence for a Differential Processing in Lobes of the Pituitary
Overview
Authors
Affiliations
The distribution of peptides derived from the novel opioid peptide precursor proenkephalin B (prodynorphin) was studied in lobes of the pituitary with antibodies against alpha-neoendorphin (alpha-neo-E) beta-neoE, dynorphin (DYN)-(1-17), DYN-(1-8), and DYN B in combination with gel filtration and high pressure liquid chromatography. In the posterior pituitary, all five opioid peptides occurred in high and about equimolar concentrations, whereas putative precursor peptides were found in only minor quantities. In contrast, in the anterior pituitary immunoreactive (ir-) DYN-(1-17) and ir-DYN B consisted exclusively of a common precursor species with a mol wt of about 6000. Six thousand-dalton DYN may be comprised of the C-terminal portion of proenkephalin B, with the sequence of DYN-(1-17) at its N-terminus. Moreover, the major portions of ir-alpha-neo-E and ir-beta-neoE in the anterior pituitary were found to be of an apparent mol wt of 8000. These findings indicate a differential processing of the opioid peptide precursor proenkephalin B in the two lobes of the pituitary. The anterior pituitary seems to process proenkephalin B predominantly into high mol wt forms of neo-E and DYNs, whereas in the posterior pituitary proenkephalin B undergoes further proteolytic processing to the smaller opioid peptides alpha-neo-E, beta-neo-E, DYN-(1-17), DYN-(1-8), and DYN B. Thus, processing differences may enable the selective liberation of different (opioid) peptides with distinct biological properties from one precursor within different tissues.
Enhanced dynorphin expression and secretion in pancreatic beta-cells under hyperglycemic conditions.
Movahed M, Louzada R, Blandino-Rosano M Mol Metab. 2024; 92:102088.
PMID: 39736444 PMC: 11846442. DOI: 10.1016/j.molmet.2024.102088.
Pierzchala-Koziec K, Scanes C Front Physiol. 2023; 14:1164031.
PMID: 37346481 PMC: 10280075. DOI: 10.3389/fphys.2023.1164031.
Considerations on Using Antibodies for Studying the Dynorphins/Kappa Opioid Receptor System.
Chen C, Widmann M, Schwarzer C, Liu-Chen L Handb Exp Pharmacol. 2021; 271:23-38.
PMID: 34085120 PMC: 9125580. DOI: 10.1007/164_2021_467.
30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.
Schwarzer C Pharmacol Ther. 2009; 123(3):353-70.
PMID: 19481570 PMC: 2872771. DOI: 10.1016/j.pharmthera.2009.05.006.
Liebisch D, Weber E, Kosicka B, Gramsch C, Herz A, Seizinger B Proc Natl Acad Sci U S A. 1986; 83(6):1936-40.
PMID: 3456613 PMC: 323199. DOI: 10.1073/pnas.83.6.1936.